Abeona Therapeutics, Inc

Quick facts

Phase 3 pipeline

• EB-101 · Neurology
  EB-101 is a gene therapy that delivers a functional copy of the ABCD1 gene to restore adrenoleukodystrophy protein function in patients with cerebral adrenoleukodystrophy.
• MSI-78 · Infectious Disease
  MSI-78 is an antimicrobial peptide that disrupts bacterial cell membranes to treat infections caused by multidrug-resistant pathogens.

Phase 2 pipeline

• ABO-101 · Hematology/Oncology
  ABO-101 is a gene therapy that delivers a functional copy of the FANCC gene to correct Fanconi anemia complementation group C deficiency.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Abeona Therapeutics, Inc portfolio CI brief
• Abeona Therapeutics, Inc pipeline updates RSS